Detalles de la búsqueda
1.
Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient-reported symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trials.
J Eur Acad Dermatol Venereol
; 2023 Feb 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36840396
2.
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.
J Eur Acad Dermatol Venereol
; 37(10): 2016-2027, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37262309
3.
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
J Eur Acad Dermatol Venereol
; 37(10): 2047-2055, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37319109
4.
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.
Br J Dermatol
; 186(3): 466-475, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34652810
5.
Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.
J Eur Acad Dermatol Venereol
; 36(8): 1275-1283, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35279890
6.
Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.
J Eur Acad Dermatol Venereol
; 36(12): 2393-2400, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35920762
7.
Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.
Br J Dermatol
; 184(5): 849-856, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32652528
8.
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study.
Br J Dermatol
; 184(3): 425-436, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32479641
9.
Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.
Br J Dermatol
; 184(4): 640-651, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32531798
10.
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
Br J Dermatol
; 185(6): 1146-1159, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34105767
11.
Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
Br J Dermatol
; 185(6): 1124-1134, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33913511
12.
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).
Br J Dermatol
; 184(4): 652-662, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32652544
13.
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
Br J Dermatol
; 185(2): 323-334, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33544883
14.
Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study.
Br J Dermatol
; 185(6): 1160-1168, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33837519
15.
Network meta-analyses in psoriasis: overview and critical discussion.
J Eur Acad Dermatol Venereol
; 35(12): 2367-2376, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34506643
16.
Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach.
J Eur Acad Dermatol Venereol
; 35(2): 329-337, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33030275
17.
Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3.
J Eur Acad Dermatol Venereol
; 35(2): 450-457, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32662540
18.
Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3.
J Eur Acad Dermatol Venereol
; 35(10): 2034-2044, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34076919
19.
Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method.
J Eur Acad Dermatol Venereol
; 35(5): 1161-1175, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33480102
20.
A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE).
J Eur Acad Dermatol Venereol
; 35(3): 701-711, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32939860